Replies to post #3869 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

From paragraph 11 (page 3) of SNY’s lawsuit against HSP filed 12/14/07:

http://www.patentdocs.typepad.com/patent_docs/files/aventis_v_hospira.pdf

Upon information and belief, Hospira filed with the FDA Abbreviated New Drug Application ("ANDA") 79-101 under 21 U.S.C. § 355(j) to obtain approval or the commercial manufacture, use, and sale of Enoxaparin Sodium Injection 100 mg/mL, 3 mL vial (the "Hospira Product").